MENDUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 SEK | -3.09% |
|
+2.29% | -10.13% |
| 16/04 | Mendus AB Announces Board Changes | CI |
| 27/03 | Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 45.04M | - | - | - | - | - | |
| 48.16B | - | |||||
| 41.73B | ||||||
| 41.03B | ||||||
| 28.77B | ||||||
| 25.59B |
- Stock Market
- Equities
- IMMU Stock
- Charts Mendus AB
- Sector Chart